TELA Bio, Inc. Annual Report - How They Did This Year

I’ve put together this guide to help you understand TELA Bio’s performance over the past year. My goal is to turn complex financial filings into plain English so you can decide if this company fits your investment strategy.

1. What does this company do?

TELA Bio is a medical technology company that creates "reinforced tissue matrices." They are a challenger in the surgical market. Traditional plastic mesh can cause chronic pain and inflammation, while purely biologic materials can be weak and expensive. TELA Bio weaves a tiny amount of polymer fiber into natural sheep-derived tissue. This creates a product that is strong, flexible, and helps the body heal naturally. Their main products, OviTex and OviTex PRS, are used for hernia repair and abdominal wall reconstruction. Their newer line, LIQUIFIX, provides a sterile system for hernia surgery.

2. Financial performance

In 2025, TELA Bio brought in $80.3 million in revenue, a 16% increase over 2024. The company is currently in a growth phase, reporting a loss of $38.8 million as they scale operations. Their profit margin on goods sold reached 68% due to manufacturing efficiencies. They are investing heavily in their 150-person sales team to drive adoption, with total operating expenses at $92.1 million.

3. Why surgeons and patients choose TELA

TELA Bio offers a "Goldilocks" solution:

• The Problem: Permanent plastic mesh is cheap but often causes pain and infection. Purely biologic options are safer but lack strength and can cost over $5,000 per unit.
• The TELA Solution: By combining natural tissue with a small amount of polymer, they offer the strength of plastic with the healing benefits of natural tissue.
• Clinical Proof: In their "BRAVO" study, they reported a hernia recurrence rate of only 2.6% in high-risk patients over two years. They also price their products 20% to 40% lower than competitors, helping hospitals manage costs.

4. Financial health

As of late 2025, the company held $32.5 million in cash. They have an accumulated deficit of about $398 million. To fund ongoing operations and growth, they utilize a combination of equity offerings and a credit line with SLR Capital Partners. The company’s primary financial goal is to reach a break-even point where revenue covers their operating costs.

5. Key risks

• Supply Chain: They rely on a single supplier, Aroa Biosurgery, to manufacture their OviTex products.
• Capital Requirements: Because the company is not yet profitable, they rely on the capital markets to fund operations. Selling additional shares to raise cash can dilute existing shareholders.
• Market Adoption: Surgeons are accustomed to using low-cost plastic alternatives. TELA Bio must continue to demonstrate the clinical and economic value of their premium products to justify the higher price point compared to standard plastic mesh.

6. Competitive positioning

TELA Bio is the only company using this specific "embroidered" technology. They are actively signing contracts with large hospital networks to expand their footprint. By distributing third-party tools alongside their own, they are positioning themselves as a "one-stop shop" for surgeons, which increases their visibility and utility in the operating room.

7. Future outlook

The company is focused on long-term growth through clinical validation and market expansion. They are currently working to expand their FDA approvals into the breast reconstruction market. This segment represents a larger, more profitable opportunity that could significantly diversify their revenue streams.

What’s next? TELA Bio has a differentiated product and a clear price advantage over high-end competitors. The investment case hinges on their ability to capture enough market share from traditional plastic mesh providers to achieve profitability before their current cash reserves are exhausted.